A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer - PubMed
5 hours ago
- #Pharmacokinetics
- #Prostate Cancer
- #Radioligand Therapy
- Phase II study on 177Lu-PSMA-617 radioligand therapy in Chinese patients with metastatic castration-resistant prostate cancer.
- Study focused on pharmacokinetics, biodistribution, and organ dosimetry of the therapy.
- Compliance with Declaration of Helsinki and Good Clinical Practice Guidelines.
- Ethical approval obtained from multiple Chinese medical institutions.
- Informed consent was secured from all participants, with data deidentified for publication.
- Some authors are employees of Novartis Pharmaceuticals and hold Novartis stock.
- References include global and Chinese cancer statistics and trends.
- Systematic review on PSMA-targeted imaging and radioligand therapy mentioned.